Garden House, now part of Megalabs Group, poised to expand offerings in North America
Garden House has been the leader in providing natural-based products for the digestive market in Latin America and now in the United States for the past decade. In 2018, the company was acquired by Megalabs Group, a global pharmaceutical giant providing and distributing prescription and OTC products.
Megalabs’ experience and success in the pharmaceutical and OTC fields have created the foundation for new initiatives and plans to launch new product categories in the United States. Now, the company is poised to partner with retail and e-commerce channels to expand its offering and provide high-quality supplements for families across North America.
Here, Ignacio Bentancur, general manager for North America, explains how he’s aiming to scale-up Garden House’s presence in the northern hemisphere.
Drug Store News: What type of innovation does your company bring to the digestive category?
Ignacio Bentancur: Our main brand and household name, Prunelax, is an effective laxative made of natural senna extract, an active ingredient with several independent clinical studies confirming its safety and effectiveness. Our innovation lies in our expertise in formulating natural-based but highly effective products. For example, the first product launched was a prune jam with crushed senna leaves and pods. We are bringing products out of the medicine cabinet and to your table. The product now comes in several forms such as tablets, jam, syrup, tea and now great-tasting gummies.
[Read more: Gut check: A variety of products solve the diversity of digestive issues]
While Megalabs’ portfolio has more than 1,800 products covering all therapeutic areas, our strategy in the U.S. focuses on launching and developing the best and most versatile solutions in the supplement and OTC field, where we have plans to expand our business by launching into new product categories.
DSN: What goals are your company working toward in 2022?
IB: For the past decade, we’ve provided natural-based products for the digestive market in the U.S., developing close relationships with well-known and qualified leaders that align with our values of high-performance standards.
In this new, exciting stage, by being part of a global pharmaceutical company, we’ve developed a growth plan supported by Megalabs’ experience and success in this field, which includes increasing our marketing efforts, launching new products in the U.S., and now have entered the Canadian market this year.
We are leveraging our capabilities and market intelligence to launch and accelerate more brands into the U.S. market, while we continue being a reliable and valuable partner for our customers and promoting our mission of improving people’s health and quality of life with safe and proven solutions.
[Read more: REX Awards 2022: OTC and Preventive Health]
DSN: What else should our readers know about your company?
IB: The company has been present in the U.S. market since 2006 and has more than 30 years of experience manufacturing and commercializing OTC pharmaceuticals and nutraceuticals based on extracts from medicinal plants and vitamins and minerals.
In 2018, Garden House was acquired by Megalabs Group, a leading branded specialty pharmaceutical company focused on innovation and therapeutic solutions for Latin American markets. Megalabs is present in more than 20 countries and has a network of 17 plants and seven R&D centers that combine cutting-edge technological development with high-quality industrial production.
Backed by a trustworthy framework and a strong reputation in the medical community, Megalabs has experienced exponential growth, emerging as the market share leader in its primary markets in Latin America.
[Read more: REX Awards 2022: Natural Products]
Maintaining a focus on continuous business development and expansion, we are on a quest to conquer new markets, remaining focused on our mission of improving people’s lives with our healthcare products.